A phase I clinical trial for recurrent esophageal cancer patients showed that MAGE-A4-specific TCR-transduced T cells could survive long-term in patients and maintain reactivity against tumors, potentially benefiting patients with lower tumor burden. This evidence concerns the gene MAGEA4 and esophageal cancer.